Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SkinBioTherapeutics Plc (SBTX.L)
Newcastle upon Tyne, GB
SkinBioTherapeutics Plc is a life sciences enterprise dedicated to enhancing human health through the exploration and development of technologies that harness the power of the human microbiome. The company has developed two primary technological platforms: SkinBiotix: This innovative solution is designed to strengthen the skin's natural barrier, offer protection against infections, and promote the repair of damaged skin. AxisBiotix: Focusing on the intricate link between gut health and skin conditions, this technology aims to mitigate the symptoms experienced by individuals with psoriasis. SkinBioTherapeutics serves a wide range of industries, including cosmetic and pharmaceutical skincare, nutritional supplements, and infection control. The company maintains active collaborations with key partners: Croda Plc; the University of Manchester, for the creation of microbiome formulations that bolster the immune system; and Winclove Probiotics B.V., with whom it's developing a unique probiotic blend derived from specific bacterial species known to influence psoriasis pathways. Originally founded in 2015 as Skinbiotix Ltd, the company adopted its current name, SkinBioTherapeutics plc, in December 2016. Its operations are headquartered in Newcastle upon Tyne, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +30.77% | +13.33% | -12.82% | -19.05% | -37.04% | -46.03% | -50.72% | -35.26% | -87.31% | -35.68% | -35.68% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+283.6% ★ Q4'25: +1,932.3% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+79.9% ★ Q4'25: +58.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-18.2% Q4'25: -71.6% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-13.4% Q4'25: -46.5% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-11.1% ★ Q4'25: -69.6% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+22.3% Q4'25: +46.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-5.05× Q4'25: -0.31× (vs Q4'23)
| Metric |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
74.8K
est: 1.17M (-93.6%)
|
132.1K
est: 132.0K (+0.0%)
|
1.21M
est: 1.10M (+9.9%)
|
4.64M
est: 4.60M (+0.8%)
|
6.20M
6.20M – 6.20M
+34.8% YoY
|
8.20M
8.20M – 8.20M
+32.3% YoY
|
| EBITDA |
-2.95M
est: -477.9K (-517.8%)
|
-2.96M
est: -53.9K (-5,380.8%)
|
-2.72M
est: -449.3K (-505.8%)
|
-196.5K
est: -1.88M (+89.5%)
|
-2.53M
-2.53M – -2.53M
-34.8% YoY
|
-3.35M
-3.35M – -3.35M
-32.3% YoY
|
| EBIT |
-2.98M
est: -499.4K (-497.1%)
|
-3.00M
est: -56.3K (-5,223.1%)
|
-2.90M
est: -469.6K (-517.0%)
|
-623.1K
est: -1.96M (+68.3%)
|
-2.65M
-2.65M – -2.65M
-34.8% YoY
|
-3.50M
-3.50M – -3.50M
-32.3% YoY
|
| Net Income |
-2.79M
est: -2.87M (+2.7%)
|
-2.84M
est: -3.92M (+27.7%)
|
-2.88M
est: -3.42M (+15.9%)
|
-696.3K
est: -1.60M (+56.3%)
|
-4.6K
-4.6K – -4.6K
+99.7% YoY
|
430.4K
430.4K – 430.4K
+9,545.7% YoY
|
| SGA |
72.3K
est: 736.4K (-90.2%)
|
118.7K
est: 83.1K (+42.9%)
|
241.0K
est: 692.4K (-65.2%)
|
376.9K
est: 2.90M (-87.0%)
|
3.90M
3.90M – 3.90M
+34.8% YoY
|
5.16M
5.16M – 5.16M
+32.3% YoY
|
| EPS |
-0.02
est: -0.01 (-41.3%)
|
-0.02
est: -0.02 (+0.0%)
|
-0.02
est: -0.02 (-2.7%)
|
0.00
est: -0.01 (+55.7%)
|
0.00
0.00 – 0.00
+99.7% YoY
|
0.00
0.00 – 0.00
+9,545.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-10 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-09 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Martin Braddock Hunt | Executive Chairman | 72.8K | male |
| Emily Lorraine Bertram | CFO, Secretary & Director | — | female |
| Melissa Greenwell | Group Financial Controller | — | female |
| Rachel Parsonage | Interim CEO & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SBTX.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
